Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer


Tonyali O., Coskun U., Sener N., İNANÇ M. , Akman T., Oksuzoglu B., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, ss.2145-2151, 2012 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 138 Konu: 12
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00432-012-1296-x
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.2145-2151

Özet

Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.